You may also be interested in...
The draft updates include a new recommendation on PSA thresholds for the referral of suspected urological cancer. They also cover the staging of prostate cancer.
Following a review of additional clinical evidence collected as part CDF, NICE has recommended atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable.
NICE draft guidance recommends apalutamide plus androgen deprivation therapy (ADT) for treating prostate cancer in adults.